A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

Trial Profile

A Phase 1 Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Epacadostat (Primary)
  • Indications Non-small cell lung cancer; Urogenital cancer
  • Focus Adverse reactions
  • Acronyms ECHO-110
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 01 Aug 2017 According to an Incyte Corporation media release, in June 2017, Incyte and Roche/Genentech decided to close the ECHO-110 trial of epacadostat plus atezolizumab to further enrollment because of slow study recruitment.
    • 01 Aug 2017 Status changed from recruiting to discontinued, according to an Incyte Corporation media release.
    • 02 May 2017 Planned End Date changed from 1 Feb 2020 to 1 Nov 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top